Baseline characteristics of the patients.
Aims: The vasopressin V2 receptor antagonist, tolvaptan, has been reported to be effective in cirrhotic patients with ascites. Here, we evaluated predictors of the response to tolvaptan. Methods: A total of 97 patients with cirrhosis (60 males; median age, 63 years) who had been treated for ascites with oral tolvaptan were enrolled. Tolvaptan efficacy was defined as urine volume increase of ≥500 mL or a urine volume ≥2000 mL/day on the day following treatment. Normalization of the serum sodium (Na) level after 1 week of treatment and the posttreatment survival rate was analyzed. Results: Tolvaptan therapy resulted in effective urination in 67% of patients. A multivariate analysis revealed that the blood urea nitrogen/creatinine (BUN/Cr) ratio and urinary Na/potassium (Na/K) ratio were predictive of the tolvaptan response (p <0.05). The serum Na level was 135 (121–145) mEq/L, and normal levels were recovered in 50.0% of the patients with an initial Na level of <135 mEq/L. The posttreatment survival rate was significantly higher in patients who responded to tolvaptan therapy (p <0.05). Conclusions: The combination of the initial BUN/Cr and urine Na/K ratios and a normalized serum Na level after 1 week was predictive of a favorable outcome to tolvaptan therapy.
- vasopressin V2 receptor antagonist
- blood urea nitrogen/creatinine ratio
- urine sodium/potassium ratio
- serum sodium
Ascites accumulation is commonly observed in decompensated liver cirrhosis . The symptoms of ascites lead to a poor quality of life and prognosis . Recently, the vasopressin V2 receptor antagonist tolvaptan has been used for ascites treatment of cirrhosis in addition to spironolactone ± furosemide [3, 4]. The Japanese Society of Gastroenterology published evidence-based clinical practice guidelines in 2015 . Tolvaptan is recommended for use before ascites drainage or administration of albumin because of its high efficacy irrespective of the serum albumin level . While the serum sodium (Na) level is low in cirrhosis, it is increased in tolvaptan-treated patients because of free water clearance without accompanying Na elimination. In contrast, conventional diuretics promote hyponatremia and impair renal function. Thus, tolvaptan has benefits for the treatment of cirrhosis.
The mechanism underlying refractory ascites caused by liver cirrhosis has been hypothesized as one or more of the following [7, 8]: (1) hypo-osmotic pressure due to hypoalbuminemia; (2) a response to mesenteric and systemic vasodilation, accompanied by development of portal hypertension, which decreases the effective circulatory volume and depletes renal flow, leading to increased arginine vasopressin (AVP) release; increased AVP results in an increase in renin-angiotensin-aldosterone system activity; and (3) postsinusoidal obstruction and lymphatic edema. These multiple causative factors are associated with ascites accumulation.
Approximately 70% of tolvaptan-treated patients exhibit increased urination and achieve a reduction in body weight within 7–14 days [9, 10]. In addition to this short-term efficacy, tolvaptan also exerts long-term effects . However, factors that predict the response to tolvaptan and its effect on prognosis are unclear. In this study, we focused on predictors of the tolvaptan response and the outcome of tolvaptan therapy.
2. Patients and methods
This was a single-center, retrospective observational study performed between September 2013 and March 2016. We enrolled a total of 97 Japanese cirrhotic patients (60 males, 62%) who received tolvaptan 3.75–7.5 mg/day (Samsca™; Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan) after hospitalization for ascites treatment. They were treated with conventional diuretics.
The patients were classified as responders or nonresponders to tolvaptan therapy. Tolvaptan efficacy was defined as a urine volume increase of ≥500 mL or a urine volume ≥2000 mL/day on the day following tolvaptan treatment, as described by Ohki et al. with slight modifications . The baseline characteristics of patients, including age, sex, medications, and laboratory parameters, were evaluated. We investigated the changes in body weight and the serum Na level after 1 week of treatment and evaluated laboratory parameters. Tolvaptan was not used in patients with severe renal dysfunction (estimated glomerular filtration rate <15 mL/min/1.73 m2 or a serum creatinine [Cr] level >3.5 mg/dL) or a hepatic coma scale score >II.
This study was conducted according to the principles of the Declaration of Helsinki, and the Institutional Review Board of Tokyo Women’s Medical University Hospital (Tokyo, Japan) approved the study protocol (no. 3258-R). The results of this study, including figures and tables, were published in Hepatology Research  and were transferred with permission.
2.3. Statistical analysis
Data are presented as medians with minimum and maximum values. Significant differences between the two groups were assessed using the Mann–Whitney U-test and
3.1. Response to tolvaptan according to urination and body weight parameters
The median age of the 97 patients (62% male) receiving tolvaptan treatment was 63 years (range, 22–90 years; Table 1). The underlying liver diseases and frequency of other ascites treatments did not differ significantly. The median increase in urine volume on the day after treatment was 690 mL (range: −530 to +3490 mL), while the median urine volume was 1675 mL/day (range: 195–6630 mL/day). The distributions of urination and body weight changes and their correlations with the tolvaptan response are shown in Figure 1(a). The change in body weight after 1 week of treatment was −1.5 kg (−17.2 to +6.2 kg). A total urine volume ≥2000 mL was achieved in 40% of cases and an increase in the urine volume in ~50% of cases (Figure 1b). Approximately 40% of cases achieved a ≥2.0 kg body weight reduction after 1 week of treatment. Overall, 67% of the cases achieved the desired level of urination. In cases who responded to tolvaptan, the platelet count, urine Na level, and urine Na/potassium (K) ratio were higher, and the blood urea nitrogen (BUN)/Cr ratio was lower (Table 2). The serum Na level was 135 (121–145) mEq/L, and 39.2% of cases had an Na level of <135 mEq/L.
|Total (||Responder (||Nonresponder (|
|Age (years)||63 (22–90)||62 (22–90)||63 (37–84)||0.21|
|Sex (% of males)||62||66||53||0.21|
|Underlying hepatitis (%) (viral/metabolic/PBC)||37/39/9||32/43/11||47/31/6||0.29|
|Complication (%) (varices/HCC/hepatic encephalopathy)||67/35/23||71/35/18||59/34/31||0.37|
|Furosemide dose (mg/day)||20 (0–160)||20 (0–160)||20 (0–80)||0.96|
|Spironolactone dose (mg/day)||50 (0–400)||50 (0–400)||50 (0–400)||0.97|
|Administration of albumin (%)||62||63||59||0.65|
|CART or drainage (%)||41||38||47||0.43|
|Prognosis; death or transplantation (%)||45||37||63||0.03|
|Total (||Responder (||Nonresponder (|
|Albumin (g/dL)||2.5 (1.5–4.2)||2.5 (1.5–4.2)||2.4 (1.9–3.5)||0.88|
|Total bilirubin (mg/dL)||1.8 (0.3–52.4)||1.5 (0.5–33.0)||2.2 (0.3–52.4)||0.73|
|Platelet count (×104 μL−1)||8.6 (1.5–42.4)||9.0 (1.5–42.4)||6.4 (2.1–23.9)||0.05|
|Prothrombin time (%)||54.5 (16.3–90.3)||54.5 (16.3–90.3)||52.6 (22.6–89.0)||0.70|
|Ammonia (mg/dL)||69 (25–269)||70 (25–269)||63 (29–212)||0.97|
|α-Fetoprotein (ng/mL)||4 (1–29,292)||4 (1–4510)||6.5 (1–29,292)||0.36|
|DCP (mAU/mL)||75 (3–4994)||42 (3–4994)||324 (10–1788)||0.61|
|BUN (mg/dL)||23.4 (5.5–125.3)||21 (5.5–63.3)||27 (12.0–125.3)||0.02|
|Creatinine (mg/dL)||1.07 (0.20–3.30)||1.00 (0.42–2.12)||1.17 (0.50–3.30)||0.13|
|eGFR (mL/min/1.73 m2)||50.0 (15.0–250.6)||50.3 (18–250.6)||46.2 (15.0–108.6)||0.15|
|Serum Na (mEq/L)||135 (121–145)||136 (122–145)||133 (121–144)||0.06|
|Serum K (mEq/L)||4.2 (2.8–6.1)||3.9 (2.8–5.3)||4.3 (3.1–6.1)||0.06|
|Serum osmolarity (mOsm/L)||281 (100–317)||283 (100–317)||279 (256–299)||0.68|
|Urine osmolarity (mOsm/L)||404 (116–938)||405 (116–938)||388 (233–715)||0.63|
|Urinary Na (mEq/L)||61 (7–256)||69.5 (10–256)||39 (7–108)||<0.01|
|Urinary K (mEq/L)||21 (6–72)||20 (6–72)||22 (13–48)||0.72|
|24 h creatinine clearance (mL/min)||51.2 (7.6–124.0)||52.8 (12.4–124.0)||44.1 (7.6–92.9)||0.12|
|BUN/creatinine ratio||22.5 (6.83–138.5)||21 (5.5–138.5)||23.7 (14.4–48.3)||0.01|
|Urine Na/K ratio||2.53 (0.22–25.6)||3.31 (0.35–25.6)||2.01 (0.22–5.13)||<0.01|
|Child-pugh score||10 (7–14)||10 (7–13)||10 (8–14)||0.23|
|Model for end-stage liver disease score||14 (7–31)||14 (7–31)||16 (8–31)||0.37|
3.2. Urination-based predictors of the response to tolvaptan
Multivariate analysis revealed that the BUN/Cr ratio (odds ratio [OR], 1.08; 95% confidence interval [CI], 1.006–1.174;
|Parameter||Odds ratio||95% confidence interval|
|Urine Na/K ratio||0.59||0.366–0.855||<0.01|
|Urine Na/K ratio|
|<3.09 (||≥3.09 (|
|BUN/Cr ratio||<17.5 (||10/12 (83.3%)||8/8 (100.0%)|
|≥17.5 (||13/33 (39.4%)||19/22 (86.3%)|
3.3. Prognosis after tolvaptan treatment
Regarding the mortality rate, 44 subjects died (45.4%). The survival rate was higher in patients who responded to tolvaptan therapy, as estimated by the Kaplan–Meier analysis (Figure 3a,
After 1 week of treatment, 70.1% of the patients achieved a normal serum Na level. These patients showed a significantly higher survival rate (
The results suggest that the initial BUN/Cr and urine Na/K ratios and a normalized serum Na level after 1 week of treatment is predictive of a tolvaptan response in cirrhosis patients. The patients showing a response to tolvaptan in terms of increased urination or serum Na level had prolonged survival and a better prognosis.
Representative factors predicting a response to tolvaptan are shown in Table 5. Free water clearance , aquaporin-2/AVP , and urinary Na excretion  were reported to be predictors of a tolvaptan response in patients with cirrhosis. The combination of BUN/Cr and urine Na/K ratios was the first reported predictor of a tolvaptan response.
|Imamura et al. ||Circ J.||2013||Urine osmolality and percentage decrease in urine osmolarity||Heart failure|
|Imamura et al. ||Circ J.||2014||Urine aquaporin-2 (AQP2)/plasma arginine vasopressin||Heart failure|
|Okayama et al. ||Am J Cardiovasc Drugs||2015||Blood urea nitrogen/creatinine (BUN/Cr) ratio||Heart failure|
|Shimizu et al. ||Nephrology (Carlton)||2015||Urine urea nitrogen/BUN ratio||Heart failure|
|Iwatani et al. ||Nephron||2015||Urine osmolarity||Chronic kidney disease|
|Miyaaki et al. ||Biomed Rep.||2015||Free water clearance||Liver cirrhosis|
|Nakanishi et al. ||J Gastroenterol.||2016||Urinary AQP2/Cr ratio||Liver cirrhosis|
|Chishina et al. ||Dig Dis.||2016||Serum BUN and serum Cr||Liver cirrhosis|
|Imamura et al. ||Int J Mol Sci.||2016||Urine AQP2||Heart failure|
|Kogiso et al. ||Hepatol Res.||2016||Serum BUN/Cr and urine sodium/potassium ratios||Liver cirrhosis|
Regarding prognosis, tolvaptan reduced the rate of inhospital mortality  and evidenced longer mortality same as other diuretics in heart failure patients , although no study has assessed these parameters in cirrhotic patients. In our study, patients with a BUN/Cr <17.5 or urine Na/K ≥3.09 showed high response rates. Approximately 50.0% of tolvaptan-treated patients reached a normal serum Na level after 1 week of tolvaptan therapy. Patients who responded to tolvaptan exhibited prolonged survival compared with those who did not. Tolvaptan may improve the prognosis.
Tolvaptan has been reported to delay the onset of end-stage renal disease and to be associated with a low rate of renal function deterioration [19, 20]. Therefore, early initiation of tolvaptan is recommended to protect renal function and improve prognosis.
However, our study had limitations because hepatocellular carcinoma (HCC) affects the mortality rate of patients with cirrhosis. Therefore, HCC cases must be excluded from prognostic analyses.
In addition to the combination of an initial BUN/Cr ratio <17.5 and urine Na/K ratio ≥3.09, a normalized serum Na level after 1 week of tolvaptan therapy was predictive of a favorable outcome in cirrhotic patients with hyponatremia and ascites treated with tolvaptan.
Ginés P, Quintero E, Arroyo V, Terés J, Bruguera M, Rimola A, Caballería J, Rodés J, Rozman C. Compensated cirrhosis: Natural history and prognostic factors. Hepatology. 1987; 7:122‐128
Planas R, Montoliu S, Ballesté B, Rivera M, Miquel M, Masnou H, Galeras JA, Giménez MD, Santos J, Cirera I, Morillas RM, Coll S, Solà R. Natural history of patients hospitalized for management of cirrhotic ascites. Clinical Gastroenterology and Hepatology. 2006; 4:1385‐1394. DOI: 10.1016/j.cgh.2006.08.007
Pérez-Ayuso RM, Arroyo V, Planas R, Gaya J, Bory F, Rimola A, Rivera F, Rodés J. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system. Gastroenterology. 1983; 84:961‐968
Sherlock S, Senewiratne B, Scott A, Walker JG. Complications of diuretic therapy in hepatic cirrhosis. Lancet. 1966; 1:1049‐1052
Fukui H, Saito H, Ueno Y, Uto H, Obara K, Sakaida I, Shibuya A, Seike M, Nagoshi S, Segawa M, Tsubouchi H, Moriwaki H, Kato A, Hashimoto E, Michitaka K, Murawaki T, Sugano K, Watanabe M, Shimosegawa T. Evidence-based clinical practice guidelines for liver cirrhosis 2015. Journal of Gastroenterology. 2016; 51:629‐650. DOI: 10.1007/s00535-016-1216-y.
Sakaida I, Nakajima K, Okita K, Hori M, Izumi T, Sakurai M, Shibasaki Y, Tachikawa S, Tsubouchi H, Oka H, Kobayashi H. Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan. Journal of Gastroenterology. 2015; 50:1047‐1053. DOI: 10.1007/s00535-015-1052-5.
Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988; 8:1151‐1157
Grace JA, Herath CB, Mak KY, Burrell LM, Angus PW. Update on new aspects of the renin-angiotensin system in liver disease: Clinical implications and new therapeutic options. Clinical Science (London). 2012; 123:225‐239. DOI: 10.1042/CS20120030
Okita K, Sakaida I, Okada M, Kaneko A, Chayama K, Kato M, Sata M, Yoshihara H, Ono N, Murawaki Y. A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis. Journal of Gastroenterology. 2010; 45:979‐987. DOI: 10.1007/s00535-010-0240-6
Sakaida I, Yamashita S, Kobayashi T, Komatsu M, Sakai T, Komorizono Y, Okada M, Okita K; ASCITES 14-Day Administration Study Group. Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema. The Journal of International Medical Research. 2013; 4:835‐847. DOI: 10.1177/0300060513480089
Kogiso T, Tokushige K, Hashimoto E, Ikarashi Y, Kodama K, Taniai M, Torii N, Shiratori K. Safety and efficacy of long-term tolvaptan therapy for decompensated liver cirrhosis. Hepatology Research. 2016; 46:E194-E200. DOI: 10.1111/hepr.12547
Ohki T, Sato K, Yamada T, Yamagami M, Ito D, Kawanishi K, Kojima K, Seki M, Toda N, Tagawa K. Efficacy of tolvaptan in patients with refractory ascites in a clinical setting. World Journal of Hepatology. 2015; 7:1685‐1693. DOI: 10.4254/wjh.v7.i12.1685
Kogiso T, Yamamoto K, Kobayashi M, Ikarashi Y, Kodama K, Taniai M, Torii N, Hashimoto E, Tokushige K. Response to tolvaptan and its effect on prognosis in cirrhotic patients with ascites. Hepatology Research. 2016. In press. DOI: 10.1111/hepr.12822.
Miyaaki H, Nakamura Y, Ichikawa T, Taura N, Miuma S, Shibata H, Honda T, Nakao K. Predictive value of the efficacy of tolvaptan in liver cirrhosis patients using free water clearance. Biomedical Reports. 2015; 3:884‐886. DOI: 10.3892/br.2015.521
Nakanishi H, Kurosaki M, Hosokawa T, Takahashi Y, Itakura J, Suzuki S, Yasui Y, Tamaki N, Nakakuki N, Takada H, Higuchi M, Komiyama Y, Yoshida T, Takaura K, Hayashi T, Kuwabara K, Sasaki S, Izumi N. Urinary excretion of the water channel aquaporin 2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites. Journal of Gastroenterology. 2016; 51:620‐627. DOI: 10.1007/s00535-015-1143-3
Uojima H, Kinbara T, Hidaka H, Sung JH, Ichida M, Tokoro S, Masuda S, Takizawa S, Sasaki A, Koizumi K, Egashira H, Kako M. Close correlation between urinary sodium excretion and response to tolvaptan in liver cirrhosis patients with ascites. Hepatology Research. 2017; 47:E14-E21. DOI: 10.1111/hepr.12716
Yoshioka K, Matsue Y, Kagiyama N, Yoshida K, Kume T, Okura H, Suzuki M, Matsumura A, Yoshida K, Hashimoto Y. Recovery from hyponatremia in acute phase is associated with better in-hospital mortality rate in acute heart failure syndrome. Journal of Cardiology. 2016; 67:406‐411. DOI: 10.1016/j.jjcc.2015.12.004
Suzuki S, Yoshihisa A, Yamaki T, Sugimoto K, Kunii H, Nakazato K, Abe Y, Saito T, Ohwada T, Suzuki H, Saitoh S, Kubota I, Takeishi Y. Long-term effects and prognosis in acute heart failure treated with tolvaptan: The AVCMA trial. BioMed Research International. 2014; 2014:704289. DOI: 10.1155/2014/704289
Kimura K, Momose T, Hasegawa T, Morita T, Misawa T, Motoki H, Izawa A, Ikeda U. Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure. Journal of Cardiology. 2016; 67:399‐405. DOI: 10.1016/j.jjcc.2015.09.020
Mori T, Ohsaki Y, Oba-Yabana I, Ito S. Diuretic usage for protection against end-organ damage in liver cirrhosis and heart failure. Hepatology Research. 2017; 47:11‐22. DOI: 10.1111/hepr.12700
Imamura T, Kinugawa K, Minatsuki S, Muraoka H, Kato N, Inaba T, Maki H, Shiga T, Hatano M, Yao A, Kyo S, Komuro I. Urine osmolality estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to tolvaptan in decompensated heart failure patients. Circulation Journal. 2013; 77:1208‐1213
Imamura T, Kinugawa K, Fujino T, Inaba T, Maki H, Hatano M, Yao A, Komuro I. Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. Circulation Journal. 2014; 78:2240‐2249
Okayama D, Suzuki T, Shiga T, Minami Y, Tsuruoka S, Hagiwara N. Blood urea nitrogen/creatinine ratio and response to tolvaptan in patients with decompensated heart failure: A retrospective analysis. American Journal of Cardiovascular Drugs. 2015; 15:289‐293. DOI: 10.1007/s40256-015-0121-8
Shimizu K, Doi K, Imamura T, Noiri E, Yahagi N, Nangaku M, Kinugawa K. Ratio of urine and blood urea nitrogen concentration predicts the response of tolvaptan in congestive heart failure. Nephrology (Carlton). 2015; 20:405‐412
Iwatani H, Kawabata H, Sakaguchi Y, Yamamoto R, Hamano T, Rakugi H, Isaka Y. Urine osmolarity predicts the body weight-reduction response to tolvaptan in chronic kidney disease patients: A retrospective, observational study. Nephron. 2015; 130:8‐12. DOI: 10.1159/000381859
Chishina H, Hagiwara S, Nishida N, Ueshima K, Sakurai T, Ida H, Minami Y, Takita M, Kono M, Minami T, Iwanishi M, Umehara Y, Watanabe T, Komeda Y, Arizumi T, Kudo M. Clinical factors predicting the effect of tolvaptan for refractory ascites in patients with decompensated liver cirrhosis. Digestive Diseases and Sciences. 2016; 34:659‐664. DOI: 10.1159/000448828
Imamura T, Kinugawa K. Urine aquaporin-2: A promising marker of response to the arginine vasopressin type-2 antagonist, tolvaptan in patients with congestive heart failure. International Journal of Molecular Sciences. 2016; 17(105):1-7. DOI: 10.3390/ijms17010105